High willingness to use injectable antiretroviral therapy among women who have been lost to follow‐up from HIV programmes: A nested cross‐sectional study. Issue 4 (23rd February 2022)

• Record Type: Journal Article
• Authors: Odongpiny, Eva Laker Agnes; Cresswell, Fiona; Arinaitwe, Arnold; Nakate, Vivian; Kyenkya, Joshua; Lamorde, Mohammed; Waitt, Catriona; Meya, David; Kiragga, Agnes
• Other Names: Gilleece Yvonne guestEditor.
• Is Part Of: HIV medicine. Volume 23:Issue 4(2022)
• Page Start: 319
• Page End: 323
• Publication Date: 2022-02-23
• Subjects: HIV/AIDS -- injectable ART -- loss to follow‐up -- nursing -- pregnant -- PVT programme; HIV infections -- Treatment -- Periodicals; HIV-positive persons -- Periodicals; HIV infections -- Treatment -- Decision making -- Periodicals; 616.9792
• DOI: 10.1111/hiv.13260
• Languages: English
• ISSNs: 1464-2662

Abstract

Abstract: Objectives: Efforts to achieve zero transmission of HIV to infants born to women living with HIV in sub‐Saharan African are undermined by high rates of loss to follow‐up in prevention of vertical transmission (PVT) programmes. The fear of HIV status disclosure through the discovery of pill bottles at home is a major contributor. Injectable antiretroviral therapy (ART) has proved to be efficacious in clinical trials and is discreet, offering a potential solution. We investigated the knowledge and willingness to use injectable ART among women who were lost to follow‐up from the PVT programme in Uganda. Methods: Women were traced by nurse counsellors and knowledge and opinions relating to injectable ART, including willingness to use it when it becomes available, were collected. Generalized linear models were used to determine predictors of willingness to use injectable ART. Conclusions: Among 1023 women registered between 2017 and 2019 under the PVT programmes in Kampala and Wakiso districts, Uganda, 385 (38%) were lost to follow‐up from care and 22% of these (83/385) were successfully traced and interviewed. Only 25% (21/83) had heard of injectable ART. Over half (55%, 46/83) were very willing to use injectable ART, 40% (33/83) were somewhat willing and four (5%) were not willing. Those who associated ART tablets with disclosure risk were more willing to consider injectable ART (adjusted odds ratio = 4.21; 95% confidence interval: 1.45–12.19; p = 0.008). We report high willingness to use injectable ART associated with fears that ART tablets were a potential source of HIV status disclosure. Injectable ART could be a solution for women who have challenges with disclosure.